Navigation Links
New statistical model could help reduce breast-lesion biopsies
Date:11/29/2008

SEATTLE A new method of characterizing breast lesions found during an MRI exam could result in fewer biopsies of benign tumors with the benefits of reduced pain and expense for patients and providers, according to a paper that will be presented today (Sunday, Nov. 30) at the annual meeting of the Radiological Society of North America (RSNA).

Wendy DeMartini, M.D., and colleagues in the breast imaging department at the Seattle Cancer Care Alliance developed a preliminary statistical model that breast radiologists could use eventually when deciding whether a lesion found on breast MRI is likely to be malignant or benign. Their retrospective review of almost 2,600 breast MRI exams performed during a four-year period at the SCCA found three crucial patient and lesion characteristics that, when used in combination, could predict the likelihood of malignancy, including identifying some lesions with probabilities of cancer close to zero.

Such a model, if confirmed by more research, could be beneficial because MRI exams are so sensitive that they reveal cancerous and non-cancerous lesions that often look alike and behave similarly when contrast dye is injected into the patient. Biopsy is often necessary to determine whether a lesion is cancerous. Statistical models may improve the ability to distinguish between such lesions and avoid unnecessary biopsies.

The researchers looked at several patient and lesion characteristics that radiologists take into account now when deciding whether a biopsy is required for diagnosis. They found three categories of characteristics that, when taken together, were the best at predicting malignancy. These were the reason that the women was having a breast MRI, the size of the lesion, and the lesion enhancement pattern from the the MRI contrast dye.

Lesions found in women undergoing MRI to look for additional malignancy after new breast cancer diagnosis, lesions that were found to be larger than one centimeter, and those whose enhancement quickly faded (called washout) were the most likely to be malignant, according to DeMartini, who is an assistant professor in the University of Washington School of Medicine.

In contrast, breast lesions found in women being screened because they are considered to be at high risk for developing cancer, that were found to be small lesions and increased their enhancement over time were very likely to benign.

"If the lesions had those three characteristics, the likelihood of malignancy was 1 percent," said DeMartini. "This is so close to zeros that rather than doing a biopsy we could instead follow the patient by doing another MRI in a few months, or we may not need to do any additional testing."

DeMartini cautioned that more research is needed before this statistical model can be validated for use as standard practice.

"This is a preliminary model. Future work will look at additional patient and lesion features and in the longer term we need to examine lesions from multiple practice sites," she said. "Our goal is to identify a group of lesions that we currently recommend for additional tests where the likelihood of cancer is so low that we can safely avoid additional testing."


'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-605-0311
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
2. Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
3. In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
4. Statistical Bowl - How the 07 Patriots and the 72 Dolphins Match Up
5. Academy of General Dentistry Releases Updated Employment Statistical Map
6. Chromatin remodeling complex connected to DNA damage control
7. Health care incentive model offers collaborative approach
8. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
9. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, to Address National Drug Crisis, Keynote Grand Opening of New Allenwood, PA National Model Detox Center
10. A classic method for modeling skin cancer is featured in Cold Spring Harbor Protocols
11. New knock-out gene model provides molecular clues to breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... Order Custom Tee ... website. No need to be concerned about garment selection, expensive graphic designers, ... all orders are printed and shipped within 5-10 days. And every garment ...
(Date:9/25/2017)... College Station, TX (PRWEB) , ... September 25, ... ... cleanroom solutions, will further expand its Portable, Continuous, Miniature, and Modular (PCMM) collaboration ... into the existing POD-based Oral Solid Dosage line. The new PODs will provide ...
(Date:9/25/2017)... ... 2017 , ... Bobbie Horowitz was hardly able to walk without excruciating pain ... cabaret and theater producer, Horowitz would manage to get to rehearsals on time, but ... City, so she had to take a cab everywhere. , It wasn’t until ...
(Date:9/25/2017)... ... September 25, 2017 , ... Ron Norman, CEO of ... senior, upper-level executives speaking at a business luncheon today, "It is tantamount to ... an asset to be fully realized and activated by the corporations that recognize ...
(Date:9/25/2017)... ... September 25, 2017 , ... “The ... a gripping look at the religious stand in the sensitive matter of ... and compassion. “The Ministry of Reconciliation: A Compassionate and Realistic Approach to Evangelizing ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform ... leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led ...
(Date:9/13/2017)... , Sept. 13, 2017   OrthoAtlanta has been ... Atlanta Football Host Committee (AFHC) for the 2018 College Football ... 8, 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... the AFHC "I,m In" campaign, participating in many activities leading ... ...
Breaking Medicine Technology: